



## **ISO 13485 Certification Achieved by RegenesiS Biomedical**

*Significant milestone towards international market commercialization*

Scottsdale, Arizona, May 9, 2011 -- RegenesiS Biomedical, Inc., a medical technology company that markets the Provant<sup>®</sup> Therapy System, announced today certification of their quality management system to the International Organization for Standardization (ISO) 13485:2003 standard. 13485 is a global standard specifically for medical device quality systems.

The ISO standard is intended to ensure that medical device manufacturers have the required quality management systems in place to safely design, manufacture and distribute medical devices. This registration certifies that RegenesiS Biomedical's quality systems conform to these requirements.

"We are pleased that our high standards for exceeding clinician and patient requirements are recognized by a leading organization," said Steve Soderberg, Vice President of Operations, of RegenesiS Biomedical. "We look forward to further progress as we advance towards international commercialization of Provant."

### About RegenesiS Biomedical

RegenesiS Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. RegenesiS developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

### About the Provant<sup>®</sup> Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: RegenesiS Biomedical, Inc.  
Scott Robey, Vice President Marketing  
[www.regenesibio.com](http://www.regenesibio.com)  
480-970-4970 phone

SOURCE: RegenesiS Biomedical Inc.